Lupin gets USFDA approval for gSprivia

22 Jun 2023 , 02:28 PM

Lupin received final approval from the US Food and Drug Administration on June 21 for its generic version of Boehringer Ingelheim’s Spiriva Handihaler (Spiriva), bringing relief to the company struggling with declining margins.

Lupin’s generic version of the drug, a bronchial asthma inhaler, will be the first to hit the market, with high margins and little competition.

Lupin expects to generate $70-100 million (Rs 500-800 crore) from the product in FY24, assuming 50% price erosion and a gradual increase in market share.

Lupin’s success in reviving US revenue growth and improving its overall margin profile was largely due to the approval of gSpiriva. As a result of the positive sentiment, the stock gained more than 5% on Wednesday.

At around 2.15 PM, Lupin was trading 3.05% lower at Rs 848.35, against the previous close of Rs 875.05 on NSE. The counter touched an intraday high of Rs 868.95 in today’s trade.

For feedback and suggestions, write to us at [e-mail]